Managed Care Outlook

U.S. asthma drug costs to jump 50% by 2023


Spending on medications to fight asthma will increase from $16 billion in 2013 to $23 billion in 2023 in the eight countries where most of these drugs are purchased, and one of the main drivers will be new products for severe asthma, according to a study by the consulting company GlobalData.

“The class of fixed-dose combinations (FDCs) of inhaled corticosteroids ... and long-acting beta-agonists ... is the leading drug class in terms of market value,” the study states, “and currently captures almost half of the total asthma market; however, its market share will shrink to 23% as targeted biologics for the treatment of severe asthma enter the market over the forecast period and start dominating the space, growing from 8.7% to 32% of the total asthma sales.”

Providers “will see a clear shift toward personalized medicine for the treatment of severe asthmatics.... It is now clear that severe asthma is not a single disease, but rather, consists of several clinical phenotypes, each having a unique underlying pathological pathway,” the study states.

The researchers add, “The uptake of these novel drugs will be a major driver of the asthma market growth and will offset the dip in sales caused by Singulair’s (montelukast’s) recent patent expiry and the patent expiry of numerous short-acting beta-agonist … products by 2017.”

Asthma: Key Metrics, 2013–2023
2013 epidemiology
Asthma-diagnosed prevalent population 60.6 million
Asthma-treated population 40.5 million
2013 market sales
United States $10.1B
Worldwide $15.9B
Pipeline assessment
Number of drugs in phase 2b–3 8
Number of first-in-class drugs 5
Most promising pipeline drugs Peak-year sales
GlaxoSmithKline’s (GSK’s) fluticasone furoate $1.7B
Sanofi/Regeneron’s dupilumab $1.1B
GSK’s Bosatria (mepolizumab) $863M
Teva’s Cinquil (reslizumab) $863M
Roche’s quilizumab $753M
Key events (2013–2023) Level of impact
Symbicort (budesonide/formoterol fumarate) patent expiration in 2014 ↓ ↓ ↓
Launch of fluticasone furoate in 2015 ↑↑↑
Advair Diskus (fluticasone propionate/salmeterol) patent expiration in 2016 ↓ ↓ ↓
Flovent (fluticasone propionate) patent expiration in 2016 ↓ ↓
Launch of Bosatria in 2016 ↑↑
2023 projected market sales
United States $15.3B
Worldwide $23.1B
Source: Asthma – Global Drug Forecast and Market Analysis to 2023, GlobalData, August 2014

UP NEXT

Managed Care
By Peter Wehrwein
Managed Care
By Peter Wehrwein
2019 Year in Preview
By Richard Mark Kirkner